INDV — Indivior PLC Stock Price, Chart & AI Report

Positive Jan 28, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

Indivior Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on February 26, 2026, followed by a leadership webcast. The company also completed its redomiciliation from the United Kingdom to the United States and provided 2026 financial guidance projecting total net revenue between $1,125-$1,195 million, with SUBLOCADE net revenue expected at $905-$945 million.

INDV financial results webcast redomiciliation opioid use disorder SUBLOCADE revenue guidance long-acting injectable

Sentiment note

The company is providing specific revenue guidance for 2026 and has successfully completed its redomiciliation to the US, which are strategic corporate actions. The guidance range suggests stable to growing revenue expectations, and the company maintains its market leadership position in OUD treatments with SUBLOCADE as a key revenue driver.

Positive Oct 30, 2025 • 18:18 UTC The Motley Fool • Lee Samaha

Here's Why Indivior Stock Soared 15% Today

Indivior reported strong Q3 results, upgrading full-year guidance for Sublocade sales to $825-$845 million. The company is executing a three-phase growth strategy focused on increasing U.S. sales and achieving expense savings.

INDV Sublocade opioid use disorder pharmaceutical sales growth restructuring

Sentiment note

Company showed strong sales growth (7% increase in Sublocade sales), upgraded financial guidance, and outlined a strategic plan for future expansion with planned expense savings and potential acquisitions

Neutral Jul 25, 2025 • 14:51 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

ANEB INDV Cannabis Use Disorder CUD pipeline drug development clinical trials

Sentiment note

Noted as a key player with a pipeline product INDV-5004, but no specific performance details provided

Positive Jun 5, 2025 • 05:00 UTC GlobeNewswire Inc. • N/A

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.

ADXN INDV Addex Therapeutics GABAB cough positive allosteric modulator

Sentiment note

The article mentions that Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies, suggesting a positive collaboration between the two companies.

Positive Apr 28, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

ADIL CMND BTAI INDV substance use disorder alcohol use disorder cocaine use disorder opioid use disorder

Sentiment note

The company's INDV-2000 is listed as an investigational therapy for opioid use disorder.

Negative Oct 10, 2024 • 13:28 UTC Benzinga • Benzinga Editor

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Indivior cuts its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue amid competition from a competing injectable product, leading to a decline in the company's stock price.

INDV Indivior SUBLOCADE revenue guidance competition

Sentiment note

Indivior cut its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue, which was impacted by competition from a competing injectable product. This led to a decline in the company's stock price.

Negative Sep 30, 2024 • 23:29 UTC GlobeNewswire Inc. • N/A

Indivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff Motion

Indivior PLC investors are advised to contact the Portnoy Law Firm to recover losses from alleged corporate wrongdoing during the class period of February 22, 2024 to July 8, 2024. The complaint claims the company exaggerated its ability to predict the impact of legislation, inflated financial outlooks, and made misleading statements about its business and prospects.

INDV Indivior PLC Portnoy Law Firm class action corporate wrongdoing

Sentiment note

The article suggests that Indivior PLC made misleading statements and exaggerated its financial outlook, leading to losses for investors during the class period. This indicates a negative sentiment towards the company.

Negative Sep 30, 2024 • 17:56 UTC GlobeNewswire Inc. • N/A

Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV

Indivior PLC (INDV) is facing a class action lawsuit alleging securities fraud between February 22, 2024 and July 8, 2024. The lawsuit claims the company made false statements and concealed information about the negative impact of certain legislation on its financial prospects and the performance of its products.

INDV Indivior PLC class action lawsuit securities fraud

Sentiment note

The article reports that Indivior PLC is facing a class action lawsuit alleging securities fraud, which suggests the company's actions and performance were not favorable for investors.

Negative Sep 30, 2024 • 12:45 UTC Benzinga • Prnewswire

INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm

Indivior PLC is facing a securities fraud lawsuit for allegedly making false and misleading statements about its products and financial performance, leading to investor losses.

INDV Indivior PLC securities fraud class action lawsuit

Sentiment note

The article alleges that Indivior made false and misleading statements about its products and financial performance, leading to a securities fraud lawsuit and investor losses.

Negative Sep 29, 2024 • 12:40 UTC GlobeNewswire Inc. • N/A

הודעה על תאריך אחרון לתביעה נגד INDV: רוזן, יועץ גלובלי מדורג ביותר, מעודד את משקיעי Indivior PLC שצברו הפסדים של יותר מ- 100 אלף דולר, להבטיח ייעוץ לפני תאריך יעד חשוב של 1 באוקטובר בתביעה ייצוגית בניירות ערך – INDV

Rosen Law Firm, a global investor rights law firm, reminds Indivior PLC (NASDAQ: INDV) investors who purchased the company's securities between February 22, 2024 and July 8, 2024 of the important October 1, 2024 deadline to seek lead plaintiff status in a securities class action lawsuit against the company.

INDV Indivior PLC securities class action investor losses

Sentiment note

The article discusses a securities class action lawsuit against Indivior PLC, alleging that the company made false and misleading statements about its business, operations, and prospects during the class period, which resulted in investor losses.

Negative Sep 29, 2024 • 12:40 UTC GlobeNewswire Inc. • N/A

INDV DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Indivior PLC Investors with Losses in Excess of $100K to Secure Counsel Before Important October 1 Deadline in Securities Class Action – INDV

Rosen Law Firm, a global investor rights law firm, is reminding investors of Indivior PLC (NASDAQ: INDV) who purchased securities during the class period of February 22, 2024 to July 8, 2024 about the important October 1, 2024 lead plaintiff deadline in a securities class action lawsuit.

INDV Indivior PLC securities class action lead plaintiff

Sentiment note

The article mentions that a securities class action lawsuit has been filed against Indivior PLC, alleging that the company made false and misleading statements regarding its business, operations, and prospects during the class period, which resulted in investor losses.

Negative Sep 25, 2024 • 12:45 UTC Benzinga • Prnewswire

INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm

Indivior PLC is facing a securities fraud lawsuit for allegedly making false and misleading statements about its products and financial performance. The Schall Law Firm is encouraging INDV investors to join the lawsuit.

INDV Indivior PLC securities fraud lawsuit

Sentiment note

The article alleges that Indivior made false and misleading statements about its products and financial performance, which led to investor losses. This suggests the company's actions were detrimental to investors.